Reig Jofre submits results note on fourth quarter of 2021
REIG JOFRE’s revenues and EBITDA grew by 3% in 2021
REIG JOFRE, in its commitment to society and the pandemic situation, has made a significant effort in 2021 to make the new injectables plant in Barcelona available and adapted to the manufacturing requirements of COVID-19 vaccines in case of future need.
At year-end 2021, listed company REIG JOFRE achieved €236 million in sales, a 3% increase over the same period of the previous year. In 2021 there is a lower consumption of antibiotics and essential products linked to COVID-19, which is offset by growth in prescription and consumer healthcare products, especially at the international level. EBITDA grew by 3%, reaching €27.3 million.
The Pharmaceutical Technologies division, devoted to injectable and antibiotic products, had a decrease in its revenue, while there is already a clear recovery in the Specialty Pharmacare division, focused on prescription medical products, and in Consumer Healthcare, particularly in the FORTE PHARMA brand in French and Benelux markets.